DrugPatentWatch Database Preview
NEUTREXIN Drug Profile
see a sample report or, see our see our flat-rate plans
When do Neutrexin patents expire, and what generic alternatives are available?
This drug has six patent family members in six countries.
The generic ingredient in NEUTREXIN is trimetrexate glucuronate. There is one drug master file entry for this compound. Additional details are available on the trimetrexate glucuronate profile page.
Summary for NEUTREXIN
| International Patents: | 6 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 4 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NEUTREXIN at DailyMed |
Medical Subject Heading (MeSH) Categories for NEUTREXIN
US Patents and Regulatory Information for NEUTREXIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-002 | Jul 31, 1998 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for NEUTREXIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-002 | Jul 31, 1998 | ➤ Sign Up | ➤ Sign Up |
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | ➤ Sign Up | ➤ Sign Up |
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | ➤ Sign Up | ➤ Sign Up |
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for NEUTREXIN
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,258,952 | Thermally stable trimetrexates and processes for producing the same | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for NEUTREXIN
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 9959981 | ➤ Sign Up |
| European Patent Office | 1080079 | ➤ Sign Up |
| Brazil | 9910543 | ➤ Sign Up |
| Canada | 2333274 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
